This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

SEQUENCE LISTING





<120> Nucleic Acids Encoding a G-Protein Coupled Receptor Involved in Sensory Transduction

<130> 02307E-088610US

<140> US 09/361,652

<141> 1999-07-27

<150> US 60/094,465

<151> 1998-07-28

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 840

<212> PRT

<213> Rattus sp.

<2205

<223> rat G-protein coupled receptor B3 (GPCR-B3)

<400> 1

Met Leu Phe Trp Ala Ala His Leu Leu Leu Ser Leu Gln Leu Val Tyr $1 \hspace{1cm} 5 \hspace{1cm} 10 \hspace{1cm} 15$

Cys Trp Ala Phe Ser Cys Gln Arg Thr Glu Ser Ser Pro Gly Phe Ser 20 25 30

Leu Pro Gly Asp Phe Leu Leu Ala Gly Leu Phe Ser Leu His Gly Asp $35 \hspace{1cm} 40 \hspace{1cm} 45$

Cys Leu Gln Val Arg His Arg Pro Leu Val Thr Ser Cys Asp Arg Pro 50 55 60

Asp Ser Phe Asn Gly His Gly Tyr His Leu Phe Gln Ala Met Arg Phe 65 70 75 80

Thr Val Glu Glu Ile Asn Asn Ser Ser Ala Leu Leu Pro Asn Ile Thr \$85\$ 90 95

Leu Gly Tyr Glu Leu Tyr Asp Val Cys Ser Glu Ser Ala Asn Val Tyr 100 105 110

Ala Thr Leu Arg Val Leu Ala Leu Gln Gly Pro Arg His Ile Glu Ile 115 120 125

Gln Lys Asp Leu Arg Asn His Ser Ser Lys Val Val Ala Phe Ile Gly 130 135

Pro Asp Asn Thr Asp His Ala Val Thr Thr Ala Ala Leu Leu Gly Pro 150 155 Phe Leu Met Pro Leu Val Ser Tyr Glu Ala Ser Ser Val Val Leu Ser 165 170 Ala Lys Arg Lys Phe Pro Ser Phe Leu Arg Thr Val Pro Ser Asp Arg His Gln Val Glu Val Met Val Gln Leu Gln Ser Phe Gly Trp Val 200 Trp Ile Ser Leu Ile Gly Ser Tyr Gly Asp Tyr Gly Gln Leu Gly Val 215 Gln Ala Leu Glu Glu Leu Ala Val Pro Arg Gly Ile Cys Val Ala Phe Lys Asp Ile Val Pro Phe Ser Ala Arg Val Gly Asp Pro Arg Met Gln 245 250 Ser Met Met Gln His Leu Ala Gln Ala Arg Thr Thr Val Val Val Val 265 Phe Ser Asn Arg His Leu Ala Arg Val Phe Phe Arg Ser Val Val Leu 280 Ala Asn Leu Thr Gly Lys Val Trp Val Ala Ser Glu Asp Trp Ala Ile 295 Ser Thr Tyr Ile Thr Ser Val Thr Gly Ile Gln Gly Ile Gly Thr Val 310 Leu Gly Val Ala Val Gln Gln Arg Gln Val Pro Gly Leu Lys Glu Phe 325 330 Glu Glu Ser Tyr Val Arg Ala Val Thr Ala Ala Pro Ser Ala Cys Pro Glu Gly Ser Trp Cys Ser Thr Asn Gln Leu Cys Arg Glu Cys His Thr 360 Phe Thr Thr Arg Asn Met Pro Thr Leu Gly Ala Phe Ser Met Ser Ala Ala Tyr Arg Val Tyr Glu Ala Val Tyr Ala Val Ala His Gly Leu His 390 Gln Leu Leu Gly Cys Thr Ser Glu Ile Cys Ser Arg Gly Pro Val Tyr 405 410 Pro Trp Gln Leu Leu Gln Gln Ile Tyr Lys Val Asn Phe Leu Leu His 425 Glu Asn Thr Val Ala Phe Asp Asp Asn Gly Asp Thr Leu Gly Tyr Tyr 440 Asp Ile Ile Ala Trp Asp Trp Asn Gly Pro Glu Trp Thr Phe Glu Ile 455

Ile Gly Ser Ala Ser Leu Ser Pro Val His Leu Asp Ile Asn Lys Thr 470 Lys Ile Gln Trp His Gly Lys Asn Asn Gln Val Pro Val Ser Val Cys 490 Thr Thr Asp Cys Leu Ala Gly His His Arg Val Val Gly Ser His His Cys Cys Phe Glu Cys Val Pro Cys Glu Ala Gly Thr Phe Leu Asn Met Ser Glu Leu His Ile Cys Gln Pro Cys Gly Thr Glu Glu Trp Ala Pro Lys Glu Ser Thr Thr Cys Phe Pro Arg Thr Val Glu Phe Leu Ala 550 555 Trp His Glu Pro Ile Ser Leu Val Leu Ile Ala Ala Asn Thr Leu Leu 565 570 Leu Leu Leu Val Gly Thr Ala Gly Leu Phe Ala Trp His Phe His 585 Thr Pro Val Val Arg Ser Ala Gly Gly Arg Leu Cys Phe Leu Met Leu Gly Ser Leu Val Ala Gly Ser Cys Ser Phe Tyr Ser Phe Phe Gly Glu 615 620 Pro Thr Val Pro Ala Cys Leu Leu Arg Gln Pro Leu Phe Ser Leu Gly 630 635 Phe Ala Ile Phe Leu Ser Cys Leu Thr Ile Arg Ser Phe Gln Leu Val 645 650 Ile Ile Phe Lys Phe Ser Thr Lys Val Pro Thr Phe Tyr Arg Thr Trp Ala Gln Asn His Gly Ala Gly Leu Phe Val Ile Val Ser Ser Thr Val 680 His Leu Leu Ile Cys Leu Thr Trp Leu Val Met Trp Thr Pro Arg Pro 690 695 700 Thr Arg Glu Tyr Gln Arg Phe Pro His Leu Val Ile Leu Glu Cys Thr 710 715 Glu Val Asn Ser Val Gly Phe Leu Leu Ala Phe Thr His Asn Ile Leu 725 730 Leu Ser Ile Ser Thr Phe Val Cys Ser Tyr Leu Gly Lys Glu Leu Pro Glu Asn Tyr Asn Glu Ala Lys Cys Val Thr Phe Ser Leu Leu Asn Phe Val Ser Trp Ile Ala Phe Phe Thr Met Ala Ser Ile Tyr Gln Gly 775

Ser Tyr Leu Pro Ala Val Asn Val Leu Ala Gly Leu Thr Thr Leu Ser 790 795 Gly Gly Phe Ser Gly Tyr Phe Leu Pro Lys Cys Tyr Val Ile Leu Cys 810 805 Arg Pro Glu Leu Asn Asn Thr Glu His Phe Gln Ala Ser Ile Gln Asp 825 Tyr Thr Arg Arg Cys Gly Thr Thr 835 <210> 2 <211> 842 <212> PRT <213> Mus sp. <220> <223> mouse G-protein coupled receptor B3 (GPCR-B3) Met Leu Phe Trp Ala Ala His Leu Leu Leu Ser Leu Gln Leu Ala Val 1.0 Ala Tyr Cys Trp Ala Phe Ser Cys Gln Arg Thr Glu Ser Ser Pro Gly 25 Phe Ser Leu Pro Gly Asp Phe Leu Leu Ala Gly Leu Phe Ser Leu His Ala Asp Cys Leu Gln Val Arg His Arg Pro Leu Val Thr Ser Cys Asp Arg Ser Asp Ser Phe Asn Gly His Gly Tyr His Leu Phe Gln Ala Met Arg Phe Thr Val Glu Glu Ile Asn Asn Ser Thr Ala Leu Leu Pro Asn 90 Ile Thr Leu Gly Tyr Glu Leu Tyr Asp Val Cys Ser Glu Ser Ser Asn 120

Val Tyr Ala Thr Leu Arg Val Pro Ala Gln Gln Gly Thr Gly His Leu 115 Glu Met Gln Arg Asp Leu Arg Asn His Ser Ser Lys Val Val Ala Leu 130 Gly Pro Asp Asn Thr Asp His Ala Val Thr Thr Ala Ala Leu 160 Ser Pro Phe Leu Met Pro Leu Val Ser Tyr Glu Ala Ser Ser Val Ile 175

Leu Ser Gly Lys Arg Lys Phe Pro Ser Phe Leu Arg Thr Ile Pro Ser

Asp Lys Tyr Gln Val Glu Val Ile Val Arg Leu Leu Gln Ser Phe Gly 195 200 205

Trp Val Trp Ile Ser Leu Val Gly Ser Tyr Gly Asp Tyr Gly Gln Leu 215 Gly Val Gln Ala Leu Glu Glu Leu Ala Thr Pro Arg Gly Ile Cys Val 230 Ala Phe Lys Asp Val Val Pro Leu Ser Ala Gln Ala Gly Asp Pro Arg Met Gln Arg Met Met Leu Arg Leu Ala Arg Ala Arg Thr Thr Val Val Val Val Phe Ser Asn Arg His Leu Ala Gly Val Phe Phe Arg Ser Val 280 Val Leu Ala Asn Leu Thr Gly Lys Val Trp Ile Ala Ser Glu Asp Trp Ala Ile Ser Thr Tyr Ile Thr Asn Val Pro Gly Ile Gln Gly Ile Gly 310 315 Thr Val Leu Gly Val Ala Ile Gln Gln Arg Gln Val Pro Gly Leu Lys 330 Glu Phe Glu Glu Ser Tyr Val Gln Ala Val Met Gly Ala Pro Arg Thr 340 345 Cys Pro Glu Gly Ser Trp Cys Gly Thr Asn Gln Leu Cys Arg Glu Cys 360 His Ala Phe Thr Trp Asn Met Pro Glu Leu Gly Ala Phe Ser Met Ser Ala Ala Tyr Asn Val Tyr Glu Ala Val Tyr Ala Val Ala His Gly 390 395 Leu His Gln Leu Leu Gly Cys Thr Ser Gly Thr Cys Ala Arg Gly Pro Val Tyr Pro Trp Gln Leu Leu Gln Gln Ile Tyr Lys Val Asn Phe Leu 425 Leu His Lys Lys Thr Val Ala Phe Asp Asp Lys Gly Asp Pro Leu Gly 435 440 Tyr Tyr Asp Ile Ile Ala Trp Asp Trp Asn Gly Pro Glu Trp Thr Phe 455 460 Glu Val Ile Gly Ser Ala Ser Leu Ser Pro Val His Leu Asp Ile Asn 470 475 Lys Thr Lys Ile Gln Trp His Gly Lys Asn Asn Gln Val Pro Val Ser Val Cys Thr Arg Asp Cys Leu Glu Gly His His Arg Leu Val Met Gly 505 Ser His His Cys Cys Phe Glu Cys Met Pro Cys Glu Ala Gly Thr Phe 520

535 Trp Ala Pro Glu Gly Ser Ser Ala Cys Phe Ser Arg Thr Val Glu Phe 550 555 545 Leu Gly Trp His Glu Pro Ile Ser Leu Val Leu Leu Ala Ala Asn Thr 565 570 Leu Leu Leu Leu Leu Ile Gly Thr Ala Gly Leu Phe Ala Trp Arg 580 585 Leu His Thr Pro Val Val Arg Ser Ala Gly Gly Arg Leu Cys Phe Leu 600 Met Leu Gly Ser Leu Val Ala Gly Ser Cys Ser Leu Tyr Ser Phe Phe 615 Gly Lys Pro Thr Val Pro Ala Cys Leu Leu Arg Gln Pro Leu Phe Ser Leu Gly Phe Ala Ile Phe Leu Ser Cys Leu Thr Ile Arg Ser Phe Gln 645 650 Leu Val Ile Ile Phe Lys Phe Ser Thr Lys Val Pro Thr Phe Tyr His 660 665 Thr Trp Ala Gln Asn His Gly Ala Gly Ile Phe Val Ile Val Ser Ser 680 Thr Val His Leu Phe Leu Cys Leu Thr Trp Leu Ala Met Trp Thr Pro Arg Pro Thr Arg Glu Tyr Gln Arg Phe Pro His Leu Val Ile Leu Glu 715 710 Cys Thr Glu Val Asn Ser Val Gly Phe Leu Val Ala Phe Ala His Asn 730 Ile Leu Leu Ser Ile Ser Thr Phe Val Cys Ser Tyr Leu Gly Lys Glu 745 Leu Pro Glu Asn Tyr Asn Glu Ala Lys Cys Val Thr Phe Ser Leu Leu Leu His Phe Val Ser Trp Ile Ala Phe Phe Thr Met Ser Ser Ile Tyr Gln Gly Ser Tyr Leu Pro Ala Val Asn Val Leu Ala Gly Leu Ala Thr 790 795 785 Leu Ser Gly Gly Phe Ser Gly Tyr Phe Leu Pro Lys Cys Tyr Val Ile

805

835

Gln Asp Tyr Thr Arg Arg Cys Gly Thr Thr

Leu Asn Thr Ser Glu Leu His Thr Cys Gln Pro Cys Gly Thr Glu Glu

6

810

Leu Cys Arg Pro Glu Leu Asn Asn Thr Glu His Phe Gln Ala Ser Ile 820 825 830

840

```
<220>
```

<210> 3 <211> 777 <212> PRT <213> Homo sapiens <223> human G-protein coupled receptor B3 (GPCR-B3) Arg Ser Cys Ser Phe Asn Glu His Gly Tyr His Leu Phe Gln Ala Met 1.0 Arg Leu Gly Val Glu Glu Ile Asn Asn Ser Thr Ala Leu Leu Pro Asn Ile Thr Leu Gly Tyr Gln Leu Tyr Asp Val Cys Ser Asp Ser Ala Asn Val Tyr Ala Thr Leu Arg Val Leu Ser Leu Pro Gly Gln His His Ile Glu Leu Gln Gly Asp Leu Leu His Tyr Ser Pro Thr Val Leu Ala Val Ile Gly Pro Asp Ser Thr Asn Arg Ala Ala Thr Thr Ala Ala Leu Leu Ser Pro Phe Leu Val His Ile Ser Tyr Ala Ala Ser Ser Glu Thr Leu 105 Ser Val Lys Arg Gln Tyr Pro Ser Phe Leu Arg Thr Ile Pro Asn Asp Lys Tyr Gln Val Glu Thr Met Val Leu Leu Gln Lys Phe Gly Trp 135 Thr Trp Ile Ser Leu Val Gly Ser Ser Asp Asp Tyr Gly Gln Leu Gly 150 Val Gln Ala Leu Glu Asn Gln Ala Leu Val Arg Gly Ile Cys Ile Ala Phe Lys Asp Ile Met Pro Phe Ser Ala Gln Val Gly Asp Glu Arg Met 185 Gln Cys Leu Met Arg His Leu Ala Gln Ala Gly Ala Thr Val Val Val 200 Val Phe Ser Ser Arg Gln Leu Ala Arg Val Phe Phe Glu Ser Val Val 210 215 220 Leu Thr Asn Leu Thr Gly Lys Val Trp Val Ala Ser Glu Ala Trp Ala Leu Ser Arg His Ile Thr Gly Val Pro Gly Ile Gln Arg Ile Gly Met 250 Val Leu Gly Val Ala Ile Gln Lys Arg Ala Val Pro Gly Leu Lys Ala 265

G,

Phe Glu Glu Ala Tyr Ala Arg Ala Asp Lys Glu Ala Pro Arg Pro Cys 280 His Lys Gly Ser Trp Cys Ser Ser Asn Gln Leu Cys Arg Glu Cys Gln 295 290 300 Ala Phe Met Ala His Thr Met Pro Lys Leu Lys Ala Phe Ser Met Ser 315 Ser Ala Tyr Asn Ala Tyr Arg Ala Val Tyr Ala Val Ala His Gly Leu 330 His Gln Leu Gly Cys Ala Ser Glu Leu Cys Ser Arg Gly Arg Val 345 Tyr Pro Trp Gln Leu Leu Glu Gln Ile His Lys Val His Phe Leu Leu His Lys Asp Thr Val Ala Phe Asn Asp Asn Arg Asp Pro Leu Ser Ser 375 Tyr Asn Ile Ile Ala Trp Asp Trp Asn Gly Pro Lys Trp Thr Phe Thr 395 390 Val Leu Gly Ser Ser Thr Trp Ser Pro Val Gln Leu Asn Ile Asn Glu 405 410 Thr Lys Ile Gln Trp His Gly Lys Asn His Gln Val Pro Lys Ser Val 425 Cys Ser Ser Asp Cys Leu Glu Gly His Gln Arg Val Val Thr Gly Phe 440 His His Cys Cys Phe Glu Cys Val Pro Cys Gly Ala Gly Thr Phe Leu Asn Lys Ser Glu Leu Tyr Arg Cys Gln Pro Cys Gly Thr Glu Glu Trp 470 475 Ala Pro Glu Gly Ser Gln Thr Cys Phe Pro Arg Thr Val Val Phe Leu 485 490 Ala Leu Arg Glu His Thr Ser Trp Val Leu Leu Ala Ala Asn Thr Leu 500 505 510 Leu Leu Leu Leu Leu Gly Thr Ala Gly Leu Phe Ala Trp His Leu Asp Thr Pro Val Val Arg Ser Ala Gly Gly Arg Leu Cys Phe Leu Met Leu Gly Ser Leu Ala Ala Gly Ser Gly Ser Leu Tyr Gly Phe Phe Gly 550 Glu Pro Thr Arg Pro Ala Cys Leu Leu Arg Gln Ala Leu Phe Ala Leu 570 Gly Phe Thr Ile Phe Leu Ser Cys Leu Thr Val Arg Ser Phe Gln Leu 580 585

```
Ile Ile Ile Phe Lys Phe Ser Thr Lys Val Pro Thr Phe Tyr His Ala
                            600
Trp Val Gln Asn His Gly Ala Gly Leu Phe Val Met Ile Ser Ser Ala
                        615
                                            620
    610
Ala Gln Leu Ile Cys Leu Thr Trp Leu Val Val Trp Thr Pro Leu
625
                    630
                                        635
Pro Ala Arg Glu Tyr Gln Arg Phe Pro His Leu Val Met Leu Glu Cys
                645
                                    650
Thr Glu Thr Asn Ser Leu Gly Phe Ile Leu Ala Phe Leu Tyr Asn Gly
            660
                                665
Leu Leu Ser Ile Ser Ala Phe Ala Cys Ser Tyr Leu Gly Lys Asp Leu
                            680
Pro Glu Asn Tyr Asn Glu Ala Lys Cys Val Thr Phe Ser Leu Leu Phe
Asn Phe Val Ser Trp Ile Ala Phe Phe Thr Thr Ala Ser Val Tyr Asp
705
                    710
                                        715
Gly Lys Tyr Leu Pro Ala Ala Asn Met Met Ala Gly Leu Ser Ser Leu
                725
                                    730
Ser Ser Gly Phe Gly Gly Tyr Phe Leu Pro Lys Cys Tyr Val Ile Leu
                                745
Cys Arg Pro Asp Leu Asn Ser Thr Glu His Phe Gln Ala Ser Ile Gln
        755
                            760
                                                765
Asp Tyr Thr Arg Arg Cys Gly Ser Thr
                        775
<210> 4
<211> 2771
<212> DNA
<213> Rattus sp.
<220>
<223> rat G-protein coupled receptor B3 (GPCR-B3)
<400> 4
attcacatca gagetgtget cagecatget gggeagaggg acgaeggetg gecageatge 60
tettetggge tgeteacetg etgeteagee tgeagttggt etactgetgg gettteaget 120
gccaaaggac agagteetet ecaggettea geetteetgg ggaetteete ettgeaggte 180
tgttctccct ccatggtgac tgtctgcagg tgagacacag acctctggtg acaagttgtg 240
acaggecega cagetteaac ggecatgget accaeetett ceaagecatg eggtteaetg 300
ttgaggagat aaacaactcc tcggccctgc ttcccaacat caccctgggg tatgagctgt 360
acgacgtgtg ctcagaatct gccaatgtgt atgccaccct gagggtgctt gccctgcaag 420
ggccccgcca catagagata cagaaagacc ttcgcaacca ctcctccaag gtggtggcct 480
tcatcgggcc tgacaacact gaccacgctg tcactaccgc tgccttgctg ggtcctttcc 540
tgatgcccct ggtcagctat gaggcaagca gcgtggtact cagtgccaag cgcaagttcc 600
cgtctttcct tcgtaccgtc cccagtgacc ggcaccaggt ggaggtcatg gtgcagctgc 660
tgcagagttt tgggtgggtg tggatctcgc tcattggcag ctacggtgat tacgggcagc 720
```

tgggtgtgca ggcgctggag gagctggccg tgccccgggg catctgcgtc gccttcaagg 780 acatcgtgcc tttctctgcc cgggtgggtg acccgaggat gcagagcatg atgcagcatc 840 tggctcaggc caggaccacc gtggttgtgg tcttctctaa ccggcacctg gctagagtgt 900

```
tetteaggte egtggtgetg geeaacetga etggeaaagt gtgggtegee teagaagaet 960
gggccatete caegtacate accagegtga etgggateca aggeattggg aeggtgeteg 1020
gtgtggccgt ccagcagaga caagtccctg ggctgaagga gtttgaggag tcttatgtca 1080
gggctgtaac agctgctccc agcgcttgcc cggaggggtc ctggtgcagc actaaccagc 1140
tgtgccggga gtgccacacg ttcacgactc gtaacatgcc cacgcttgga gccttctcca 1200
tgagtgccgc ctacagagtg tatgaggctg tgtacgctgt ggcccacggc ctccaccagc 1260
teetgggatg tacttetgag atetgtteea gaggeecagt etaceeetgg eagettette 1320
agcagateta caaggtgaat titettetae atgagaatae tgtggcatti gatgacaaeg 1380
gggacactot aggttactac gacatcatcg cotgggactg gaatggacot gaatggacot 1440
tțgagatcat tggctctgcc tcactgtctc cagttcatct ggacataaat aagacaaaaa 1500
tecagtggea egggaagaac aateaggtge etgtgteagt gtgtaceaeg gaetgtetgg 1560
cagggcacca cagggtggtt gtgggttccc accactgctg ctttgagtgt gtgccctgcg 1620
aagetgggae ettteteaae atgagtgage tteacatetg eeageettgt ggaacagaag 1680
atgaacccat ctctttggtg ctaatagcag ctaacacgct attgctgctg ctgctggttg 1800
ggactgctgg cctgtttgcc tggcattttc acacacctgt agtgaggtca gctgggggta 1860
ggctgtgctt cctcatgctg ggttccctgg tggccggaag ttgcagcttc tatagcttct 1920
teggggagee caeggtgeee gegtgettge tgegteagee cetettttet etegggtttg 1980
ccatcttcct ctcctgcctg acaatccgct ccttccaact ggtcatcatc ttcaagtttt 2040
ctaccaaggt gcccacatte taccgtacet gggcccaaaa ccatggtgca ggtctattcg 2100
tcattgtcag ctccacggtc catttgctca tctgtctcac atggcttgta atgtggaccc 2160
cacgacccac cagggaatac cagcgcttcc cccatctggt gattctcgag tgcacagagg 2220
tcaactetgt aggetteetg ttggetttea eccaeaacat teteetetee ateagtacet 2280
tegtetgeag etacetgggt aaggaactge eagagaacta taatgaagee aaatgtgtea 2340
cetteageet geteeteaac ttegtateet ggategeett etteaceatg geeageattt 2400
accagggcag ctacctgcct gcggtcaatg tgctggcagg gctgaccaca ctgagcggcg 2460
getteagegg ttaetteete eccaagtget atgtgattet etgeegteea gaacteaaca 2520
atacagaaca ctttcaggcc tccatccagg actacacgag gcgctgcggc actacctgat 2580
ccactggaaa ggtgcagacg ggaaggaagc ctctcttctt gtgctgaagg tggcgggtcc 2640
agtggggccg agagcttgag gtgtctggga gagctccggc acagcttacg atgtataagc 2700
aaaaaaaaa a
                                                               2771
<210> 5
<211> 2579
<212> DNA
<213> Mus sp.
<223> mouse G-protein coupled receptor B3 (GPCR-B3)
<400> 5
tttggccagc atgcttttct gggcagctca cctgctgctc agcctgcagc tggccgttgc 60
ttactgctgg gctttcagct gccaaaggac agaatcctct ccaggtttca gcctccctgg 120
ggactteete etggeaggee tgtteteeet eeatgetgae tgtetgeagg tgagacacag 180
acctetggtg acaagttgtg acaggtetga cagetteaac ggeeatgget ateacetett 240
ccaagccatg cggttcaccg ttgaggagat aaacaactcc acagctctgc ttcccaacat 300
caccetgggg tatgaactgt atgacgtgtg etcagagtet tecaatgtet atgecaeeet 360
gagggtgccc gcccagcaag ggacaggcca cctagagatg cagagagatc ttcgcaacca 420
ctcctccaag gtggtggcac tcattgggcc tgataacact gaccacgctg tcaccactgc 480
tgccctgctg agcccttttc tgatgcccct ggtcagctat gaggcgagca gcgtgatcct 540
cagtgggaag cgcaagttcc cgtccttctt gcgcaccatc cccagcgata agtaccaggt 600
ggaagtcata gtgcggctgc tgcagagctt cggctgggtc tggatctcgc tcgttggcag 660
ctatggtgac tacgggcagc tgggcgtaca ggcgctggag gagctggcca ctccacgggg 720
catctgcgtc gccttcaagg acgtggtgcc tctctccgcc caggcgggtg acccaaggat 780
geagegeatg atgetgegte tggetegage eaggaceace gtggtegtgg tettetetaa 840
ceggeacetg getggagtgt tetteaggte tgtggtgetg gecaacetga etggeaaagt 900
gtggatcgcc tccgaagact gggccatctc cacgtacatc accaatgtgc ccgggatcca 960
gggcattggg acggtgctgg gggtggccat ccagcagaga caagtccctg gcctgaagga 1020
```

gtttgaagag teetatgtee aggeagtgat gggtgeteee agaacttgee cagaggggte 1080

```
ctggtgcggc actaaccagc tgtgcaggga gtgtcacgct ttcacgacat ggaacatgcc 1140
cgagcttgga gccttctcca tgagcgctgc ctacaatgtg tatgaggctg tgtatgctgt 1200
ggcccacggc ctccaccagc tectgggatg tacetetggg acetgtgcca gaggcccagt 1260
ctacccctgg cagettette ageagateta caaggtgaat tteettetae ataagaagae 1320
tgtagcattc gatgacaagg gggaccctct aggttattat gacatcatcg cctgggactg 1380
gaatggacct gaatggacct ttgaggtcat tggttctgcc tcactgtctc cagttcatct 1440
agacataaat aagacaaaaa tocagtggca cgggaagaac aatcaggtgc ctgtgtcagt 1500
gtgtaccagg gactgtctcg aagggcacca caggttggtc atgggttccc accactgctg 1560
cttcgagtgc atgccctgtg aagctgggac atttctcaac acgagtgagc ttcacacctg 1620
ccageettgt ggaacagaag aatgggeeee tgaggggage teageetget teteaegeae 1680
cgtggagttc ttggggtggc atgaacccat ctctttggtg ctattagcag ctaacacgct 1740
attgctgctg ctgctgattg ggactgctgg cctgtttgcc tggcgtcttc acacgcctgt 1800
tgtgaggtca gctgggggta ggctgtgctt cctcatgctg ggttccttgg tagctgggag 1860
ttgcagecte tacagettet tegggaagee caeggtgeee gegtgettge tgegteagee 1920
cetettteet etegggtttg ceatttteet eteetgtetg acaateeget cetteeaact 1980
ggtcatcatc ttcaagtttt ctaccaaggt acccacattc taccacactt gggcccaaaa 2040
ccatggtgcc ggaatattcg tcattgtcag ctccacggtc catttgttcc tctgtctcac 2100
gtggcttgca atgtggaccc cacggcccac cagggagtac cagcgcttcc cccatctggt 2160
gattettgag tgeacagagg teaactetgt gggetteetg gtggettteg cacacaacat 2220
cctcctctcc atcagcacct ttgtctgcag ctacctgggt aaggaactgc cggagaacta 2280
taacqaaqcc aaatgtgtca ccttcagcct gctcctccac ttcgtatcct ggatcgcttt 2340
cttcaccatg tccagcattt accagggcag ctacctaccc gcggtcaatg tgctggcagg 2400
gctggccact ctgagtggcg gcttcagcgg ctatttcctc cctaaatgct acgtgattct 2460
ctgccgtcca gaactcaaca acacagaaca ctttcaggcc tccatccagg actacacgag 2520
gegetgegge actacetgag gegetgegge actacetgag gegetgegge actacetga 2579
<210> 6
<211> 2333
<212> DNA
<213> Homo sapiens
<220>
<223> human G-protein coupled receptor (GPCR-B3)
aggtettgta getteaatga geatggetae eacetettee aggetatgeg gettggggtt 60
gaggagataa acaactccac ggccctgctg cccaacatca ccctggggta ccagctgtat 120
gatgtgtgtt ctgactctgc caatgtgtat gccacgctga gagtgctctc cctgccaggg 180
caacaccaca tagageteca aggagacett etecaetatt eccetaeggt getggeagtg 240
attgggcctg acagcaccaa ccgtgctgcc accacagccg ccctgctgag ccctttcctg 300
gtgcatatta gctatgcggc cagcagcgag acgctcagcg tgaagcggca gtatccctct 360
ttcctgcgca ccatccccaa tgacaagtac caggtggaga ccatggtgct gctgctgcag 420
aagttegggt ggaeetggat etetetggtt ggeageagtg aegaetatgg geagetaggg 480
gtgcaggcac tggagaacca ggccctggtc aggggcatct gcattgcttt caaggacatc 540
atgecettet etgeceaggt gggegatgag aggatgeagt geeteatgeg ceacetggee 600
caggeogggg ccaccqtcgt ggttgttttt tccagccggc agttggccag ggtgtttttc 660
gagtccgtgg tgctgaccaa cctgactggc aaggtgtggg tcgcctcaga agcctgggcc 720
ctctccaggc acatcactgg ggtgcccggg atccagcgca ttgggatggt gctgggcgtg 780
gccatccaga agagggctgt ccctggcctg aaggcgtttg aagaagccta tgcccgggca 840
gacaaggagg cccctaggcc ttgcacaagg gctcctggtg cagcagcaat cagctctgca 900
gagaatgcca agctttcatg gcacacacga tgcccaagct caaagccttc tccatgagtt 960
ctgcctacaa cgcataccgg gctgtgtatg cggtggccca tggcctccac cagctcctgg 1020
getgtgeete tgagetetgt tecaggggee gagtetacee etggeagett ttggageaga 1080
{\tt tccacaaggt\ gcatttcctt\ ctacacaagg\ acactgtggc\ gtttaatgac\ aacagagatc\ 1140}
ccctcagtag ctataacata attgcctggg actggaatgg acccaagtgg accttcacgg 1200
tecteggtte etecacatgg tetecagtte agetaaacat aaatgagace aaaateeagt 1260
ggcacggaaa gaaccaccag gtgcctaagt ctgtgtgttc cagcgactgt cttgaagggc 1320
accagegagt ggttacgggt ttccatcact getgetttga gtgtgtgeec tgtggggetg 1380
```

ggaccttcct caacaagage gagetetaca gatgecagee ttgtggaaca gaagagtggg 1440 cacetgaggg aagecagace tgetteege geactgtggt gtttttgget ttgegtgage 1500

```
acacctettg ggtgetgetg geagetaaca egetgetget getgetgetg ettgggaetg 1560
ctggcctgtt tgcctggcac ctagacaccc ctgtggtgag gtcagcaggg ggccgcctgt 1620
getttettat getgggetee etggeageag gtagtggeag eetetatgge ttetttgggg 1680
aacccacaag geetgegtge ttgetaegee aggeeetett tgeeettggt tteaccatet 1740
teetgteetg cetgaeagtt egeteattee aactaateat catetteaag tttteeacea 1800
aggtacetae attetaceae geetgggtee aaaaceaegg tgetggeetg tttgtgatga 1860
teageteage ggeceagetg ettatetgte taaettgget ggtggtgtgg acceeactge 1920
ctgctaggga ataccagcgc ttcccccatc tggtgatgct tgagtgcaca gagaccaact 1980
contaggett catactaged theotetaca atageetect etecateagt geettigeet 2040
qcaqctacct gggtaaggac ttgccagaga actacaacga ggccaaatgt gtcaccttca 2100
geotypetett caacttegtg teetggateg cettetteac caeggecage gtetaegaeg 2160
gcaagtacct gcctgcggcc aacatgatgg ctgggctgag cagcctgagc agcggcttcg 2220
gtgggtattt tctgcctaag tgctacgtga tcctctgccg cccagacctc aacagcacag 2280
agcacttcca ggcctccatt caggactaca cgaggcgctg cggctccacc tga
<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:amino acid
      sequence encoded by degenerate primer
Ile Ala Trp Asp Trp Asn Gly Pro Lys Trp
<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence
```

<223> Description of Artificial Sequence:amino acid
 sequence encoded by degenerate primer

Leu Pro Glu Asn Tyr Asn Glu Ala Lys Cys

<220>

<400> 8

10

FEB 0.7 2000 Application No.: 09/361,652

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid $\mathfrak s$	seguer	nce disclosure	e contained	in this ap	plication do	oes not
The nucleotide and/or amino acid s comply with the requirements for s	uch a	disclosuid as	set forth in	37 C.F.R	. 1.821 - 1.	825 for the
following reason(s):	KEB .	S S S S S S S S S S S S S S S S S S S				

attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990. 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.82 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damand/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification.	ng i	eason(s).
Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.82 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damand/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or	X	
 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.82 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damand/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other:	X	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.82 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be dama and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or	X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
"Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or		6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing". An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or		7. Other:
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing". An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or	αA	plicant Must Provide:
into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or	X	
applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or	X	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	X	

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE